Multiple Sclerosis and Related Disorders

The nationwide Transforming MS for All project 5:19
The nationwide Transforming MS for All project
Joela Mathews • 22 Jul 2022
Addressing the MS care paradox in the UK 3:39
Addressing the MS care paradox in the UK
Joela Mathews • 22 Jul 2022
What is the role of a neuropharmacist? 6:24
What is the role of a neuropharmacist?
Joela Mathews • 22 Jul 2022
How are MS services coping across the UK? 5:20
How are MS services coping across the UK?
Joela Mathews • 22 Jul 2022
At-home exercise and transcranial direct current stimulation (tDCS) for MS mobility 1:46
At-home exercise and transcranial direct current stimulation (tDCS) for MS mobility
Giuseppina Pilloni • 13 Apr 2022
Visual impairments in multiple sclerosis 1:15
Visual impairments in multiple sclerosis
Christian Cordano • 4 Apr 2022
Defining spinal cord reserve and its correlation with disability in MS 4:16
Defining spinal cord reserve and its correlation with disability in MS
Jaume Sastre-Garriga • 3 Apr 2022
Developments in utilizing MRI biomarkers in MS 3:07
Developments in utilizing MRI biomarkers in MS
Jaume Sastre-Garriga • 3 Apr 2022
Developments in teleinterventions: tDCS with remote supervision for MS rehabilitation 9:21
Developments in teleinterventions: tDCS with remote supervision for MS rehabilitation
Giuseppina Pilloni et al. • 13 Apr 2022
Using the visual pathway to treat MS 1:02
Using the visual pathway to treat MS
Christian Cordano • 4 Apr 2022
Utility of brain volumetry and tissue integrity in MS diagnosis 2:29
Utility of brain volumetry and tissue integrity in MS diagnosis
Jaume Sastre-Garriga • 3 Apr 2022
Major disparities in neurology care 1:39
Major disparities in neurology care
Lilyana Amezcua • 4 Apr 2022
The molecular basis of EBV triggering multiple sclerosis 3:57
The molecular basis of EBV triggering multiple sclerosis
Lawrence Steinman • 11 Apr 2022
Important lines of research in progressive multiple sclerosis 2:54
Important lines of research in progressive multiple sclerosis
Lawrence Steinman • 11 Apr 2022
The CHIMES trial: disease activity & biomarkers in minority patients treated with ocrelizumab 1:12
The CHIMES trial: disease activity & biomarkers in minority patients treated with ocrelizumab
Lilyana Amezcua • 4 Apr 2022
Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS 1:52
Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS
Lawrence Steinman • 11 Apr 2022
The content of VJNeurology is intended for healthcare professionals